ReviewNature reviews. Gastroenterology & hepatology2013
Liver transplantation: past, present and future.
Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05432765 (AIIM Trial), which is not on this map. Cited by 125 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AIIM Trial: Protecting Kidney Function After Transplantation Using Augmented Intelligence Based Immunosuppression Dosing
Who cites it
125 citing papers in PubMed, 5 syntheses or guidelines pooled it, 299 citations in OpenAlex.
- Pooled it
- Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatology international · 2024Guideline
- Global research hotspots and trends of acute rejection after liver transplantation from 1988 to 2022: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- Pooled it
- A pooled analysis of mesenchymal stem cell-based therapy for liver disease.Stem cell research & therapy · 2018Pooled it
- Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial.Nature communications · 2025Trial
- Clinical Validation of a Novel Scoring System Based on Donor and Recipient Risk Factors for Predicting Outcomes in Liver Transplantation.Annals of transplantation · 2022Trial
- Article
- Immunoglobulin κ drives liver regeneration by stabilizing MYLK to maintain cytoskeletal integrity and promote hepatocyte proliferation.Journal of translational internal medicine · 2026Article
- Full robotic liver transplantation in recipients: a narrative review of three competing surgical strategies.Journal of robotic surgery · 2026Review
- Nanozyme for precision treatment of hepatocellular carcinoma.Materials today. Bio · 2026Review
- Effect of Donor-Recipient Age Difference on Liver Transplant Outcomes.Transplantation direct · 2026Article
- Association between osteoporosis and waitlist mortality in liver transplant candidates.Scientific reports · 2026Article
- A 23-Year Comprehensive Analysis of over 4000 Liver Transplants in Türkiye: Integrating Clinical Outcomes with Public Health Insights.Healthcare (Basel, Switzerland) · 2026Article
- Mesenchymal Stem Cell-derived Exosomes in the Treatment of End-stage Liver Disease.Current stem cell research & therapy · 2026Review
- Chronic Liver Allograft Rejection: Histopathological Insights and Future Directions.Results and problems in cell differentiation · 2026Review
- Regenerating liver uses ammonia to support de novo pyrimidine synthesis and cell proliferation.Nature communications · 2025Article
- AXL activation governs the liver microenvironment to protect ischemia-reperfusion injury by suppressing NLRP3 inflammasome.Cellular & molecular biology letters · 2025Article
- Beyond preservation: future machine perfusion for liver assessment and repair.Nature reviews. Gastroenterology & hepatology · 2025Review
- Trends of liver transplantation in Asia.Updates in surgery · 2025Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first human liver transplant operation was performed by Thomas Starzl in 1963. The next two decades were marked by difficulties with donor organ quality, recipient selection, operative and perioperative management, immunosuppression and infectious complications. Advances in each of these areas transformed liver transplantation from an experimental procedure to a standard treatment for end-stage liver disease and certain cancers. From the handful of pioneering programmes, liver transplantation has expanded to hundreds of programmes in >80 countries. 1-year patient survival rates have exceeded 80% and outcomes continue to improve. This success has created obstacles. Ongoing challenges of liver transplantation include those concerning donor organ shortages, recipients with more advanced disease at transplant, growing need for retransplantation, toxicities and adverse effects associated with long-term immunosuppression, obesity and NASH epidemics, HCV recurrence and the still inscrutable biology of hepatocellular carcinoma. This Perspectives summarizes this transformation over time and details some of the challenges ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.